SQI Diagnostics appoints Rob Chioini to its Board of Directors as CEO alongside Eric Brouwer remaining to the Board as CSO

– CANADA, Toronto – SQI Diagnostics, Inc. (TSX: SQD | OTC: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced the appointment of  Rob Chioini to its Board of Directors as CEO effective August 17, 2020, succeeding Eric Brouwer who stepped down as Interim CEO and will continue to serve as the CSO and a Board director.

The appointment of Mr. Chioini as CEO and a director of SQI is subject to the approval of the TSX Venture Exchange.

“Rob is a successful entrepreneur and experienced CEO who has an exceptional track record of identifying and developing new product and revenue stream opportunities,” said Board Chairman, Clive Beddoe.

He added: “His experience in marketing and commercializing novel products to capture market share and strengthen the company brand will be invaluable as we advance our product portfolio, including our COVID19 severity assessment tests. He is a seasoned leader with a significant understanding of public markets, corporate growth and delivering value to shareholders. I look forward to Rob’s leadership, and we are fortunate to have him as our CEO.”

About Rob

Mr. Chioini founded Rockwell Medical, Inc., a Nasdaq-listed medical device and biopharmaceutical company, and served as its Chairman and CEO between 1995 and 2018. Mr. Chioini has over 30 years of operational and business development experience in the medical industry and has extensive knowledge regarding new product innovation, intellectual property, marketing and sales, distribution, customer relationships and operations, enabling him to provide critical insight into overall strategic planning, sales and marketing strategy and operational requirements. Mr. Chioini also has extensive experience in capital raising and institutional transactions. Mr. Chioini attended Michigan State University and received a Bachelor of Arts Degree in Advertising in 1987.

Mr. Chioini stated, “I am incredibly excited to assume the CEO role at SQI and about the future of the Company. I look forward to working with the team to unlock the potential across our suite of clinical and point of care diagnostic products.” Mr. Chioini further stated, “Now more than ever, we see the importance of accurate, widely available, and rapid diagnostic tests.”

About SQI Diagnostics

SQI Diagnostics is a life-sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality.

For more information: https://sqidiagnostics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>